With Tecentriq and Avastin's trial win over Sutent in first-line kidney cancer, Roche scored new points in its quest to advance the combo.
J&J and AbbVie racked up new long-term Imbruvica data that will come in handy as they try to ward off a new AstraZeneca competitor.
Three major regulatory bodies – FDA, EMA and Health Canada – changed their guidelines to drug naming. How could these changes impact drug launch timelines?
After a near-fatal heart attack, Biggest Loser's Bob Harper has teamed with Brilinta-maker AstraZeneca to reach other survivors.
Current legislation doesn't include axing pharma's advertising deduction, but paying for other tax breaks may put it on the chopping block.
Horizon has faced its share of trouble with formulary placement and specialty pharmacies, and now those woes have spread.
Dark social media may sound sinister, but it's actually just a growing way that people share content on social media, and pharma companies should be…
It’s an A-plus for J&J and Sanofi. The second annual Good Pharma Scorecard assigned both drugmakers perfect scores of 100% for trial transparency.
Clovis is one step away from a new use for its ovarian cancer drug Rubraca—and with FDA priority review, it could take that step early next year.
Allergan investors fretted Tuesday over strong data from a potential Botox competitor. But the way analysts see it, there’s not much to worry about.
Recent years have seen a wave of new biologics take the psoriasis market by storm. But a best-in-class med may still be on its way, one analyst says.